Turing Pharmaceuticals will reduce the cost of a drug after jacking up the price more than 5,000% and attracting the ire of presidential candidate Hillary Clinton and others. Chief Executive Martin Shkreli confirmed in an interview with NBC News late Tuesday that he will lower the price of Daraprim, a treatment for a specific infection that can strike those with compromised immune systems, such as AIDS and cancer patients. Shkreli increased the price from $13.50 to $750 a pill after acquiring the medication from Impax Laboratories Inc. last month. The New York Times publicized the move in a Sunday article highlighting the habit of buying older drugs and drastically increasing the prices, leading to a vocal backlash from Democratic presidential candidate Clinton and others. “I think that it makes sense to lower the price in response to the anger that was felt by people,” Shkreli told NBC News, though he did not say what the new price would be.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News